MAP2K1 and neoplasm: Furthermore, in colorectal and melanoma cell lines, TMPRSS11E has been shown to activate the AKT pathway, enabling resistance to MEK1/2-ERK inhibition, thereby contributing to treatment resistance and sustained tumor growth [23].